Plus Therapeutics Inc (PSTV) gains 3.57% for July 21

Equities Staff  |

Plus Therapeutics Inc (NASDAQ: PSTV) shares gained 3.57%, or $0.08 per share, to close Wednesday at $2.32. After opening the day at $2.24, shares of Plus fluctuated between $2.33 and $2.23. 59,451 shares traded hands a decrease from their 30 day average of 254,434. Wednesday's activity brought Plus’s market cap to $23,746,418.

Plus is headquartered in Austin, Texas..

About Plus Therapeutics Inc

Plus Therapeutics is a clinical-stage pharmaceutical company whose radiotherapeutic portfolio is concentrated on nanoliposome-encapsulated radionuclides for several cancer targets. Central to the Company's drug development is a unique nanotechnology platform designed to reformulate, deliver and commercialize multiple drugs targeting rare cancers and other diseases. The platform is designed to facilitate new delivery approaches and/or formulations of safe and effective, injectable drugs, potentially enhancing the safety, efficacy and convenience for patients and healthcare providers.

Visit Plus Therapeutics Inc’s profile for more information.

About The Nasdaq Stock Market

The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world's leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook.

To get more information on Plus Therapeutics Inc and to follow the company’s latest updates, you can visit the company’s profile page here: Plus Therapeutics Inc’s Profile. For more news on the financial markets be sure to visit Equities News. Also, don’t forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Market Movers

Sponsored Financial Content